CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

Sponsor:

AstraZeneca

Sponsor Study ID:

D8535C00001

CTO #:

104015

NCT Number:

NCT05952557

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Breast

Study Objectives:

To demonstrate superiority of camizestrant ± abemaciclib as compared to standard ET ± abemaciclib by assessment of invasive breast cancer-free survival (IBCFS). To demonstrate superiority of camizestrant ± abemaciclib as compared to standard ET ± abemaciclib by assessment of invasive disease-free survival (IDFS).

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)